Brokerages forecast that DexCom, Inc. (NASDAQ:DXCM) will post $0.02 earnings per share for the current quarter, Zacks reports. Nine analysts have issued estimates for DexCom’s earnings. The highest EPS estimate is $0.11 and the lowest is ($0.10). DexCom posted earnings of ($0.09) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 122.2%. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 27th.

On average, analysts expect that DexCom will report full-year earnings of ($0.74) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.63). For the next year, analysts forecast that the company will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.76) to $0.23. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover DexCom.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.24) EPS.

DXCM has been the topic of several recent research reports. Barclays PLC reissued an “equal weight” rating and issued a $60.00 price target (down previously from $76.00) on shares of DexCom in a report on Thursday, September 28th. Citigroup Inc downgraded DexCom from an “outperform” rating to a “market perform” rating in a report on Thursday, September 28th. Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Leerink Swann reissued a “buy” rating and issued a $57.00 price target (down previously from $85.00) on shares of DexCom in a report on Friday, September 29th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $105.00 price target on shares of DexCom in a report on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $70.69.

COPYRIGHT VIOLATION NOTICE: “$0.02 EPS Expected for DexCom, Inc. (DXCM) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/04/0-02-eps-expected-for-dexcom-inc-dxcm-this-quarter.html.

DexCom (DXCM) opened at $49.12 on Friday. The company has a current ratio of 5.86, a quick ratio of 5.84 and a debt-to-equity ratio of 0.84.

In other news, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total value of $123,050.10. Following the transaction, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at approximately $5,448,447.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $69.77, for a total value of $418,620.00. The disclosure for this sale can be found here. Insiders have sold 23,208 shares of company stock worth $1,597,567 over the last ninety days. Company insiders own 1.70% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA raised its position in shares of DexCom by 133.3% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 22,094 shares of the medical device company’s stock valued at $1,081,000 after acquiring an additional 12,623 shares during the last quarter. FDx Advisors Inc. raised its position in shares of DexCom by 47.5% during the 3rd quarter. FDx Advisors Inc. now owns 17,307 shares of the medical device company’s stock valued at $847,000 after acquiring an additional 5,576 shares during the last quarter. Global X MANAGEMENT CO LLC raised its position in shares of DexCom by 30.1% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 39,701 shares of the medical device company’s stock valued at $1,942,000 after acquiring an additional 9,185 shares during the last quarter. Pitcairn Co. raised its position in shares of DexCom by 90.8% during the 3rd quarter. Pitcairn Co. now owns 29,958 shares of the medical device company’s stock valued at $1,466,000 after acquiring an additional 14,260 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of DexCom by 3.4% during the 3rd quarter. Swiss National Bank now owns 318,400 shares of the medical device company’s stock valued at $15,578,000 after acquiring an additional 10,500 shares during the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.